Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPLEX: Thoracic Radiotherapy + Durvalumab + Chemotherapy in ES SCLC
NCT05223647Phase 3Terminated
- Sponsor
- Norwegian University of Science and Technology
- Start
- Jan 2022
- Primary completion
- Sep 2025
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) (2 arms), sponsored by Norwegian University of Science and Technology. Primary endpoint: Overall Survival at 1 year. Started Jan 2022; status: terminated.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05223647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223647.